Literature DB >> 27396505

Design and synthesis of new homo and hetero bis-piperazinyl-1-propanone derivatives as 5-HT7R selective ligands over 5-HT1AR.

Sebastiano Intagliata1, Maria N Modica2, Valeria Pittalà2, Loredana Salerno2, Maria A Siracusa2, Alfredo Cagnotto3, Mario Salmona3, Giuseppe Romeo2.   

Abstract

In this work we report the discovery of new homo and hetero bis-piperazinyl-1-propanone derivatives as selective ligands for 5-HT7 over 5-HT1A receptor. These newly synthesized compounds possess a 4-arylpiperazine linked through an acyl spacer to another substituted piperazine system and were tested for their binding properties on human cloned 5-HT1A and 5-HT7 serotonin receptors. Among these, phenyl, 4- and 2-chlorophenyl, 2-methoxyphenyl, 2-pyridyl, and 2-pyrimidyl derivatives 15, 24, 25, and 27-29 displayed nanomolar affinity values for the 5-HT7 receptor (Ki 23.5-52.0nM) and no affinity for the 5-HT1A receptor.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5-HT(7) selective ligands; Bivalent ligand approach; Hetero bis-piperazine; Homo bis-piperazine; Serotonin receptors

Mesh:

Substances:

Year:  2016        PMID: 27396505     DOI: 10.1016/j.bmcl.2016.06.080

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

Review 1.  Pharmacophore Comparison and Development of Recently Discovered Long Chain Arylpiperazine and Sulfonamide Based 5-HT7 Ligands.

Authors:  Andrea Rague; Kevin Tidgewell
Journal:  Mini Rev Med Chem       Date:  2018       Impact factor: 3.862

2.  In Vitro Antioxidant Activity of Idebenone Derivative-Loaded Solid Lipid Nanoparticles.

Authors:  Lucia Montenegro; Maria N Modica; Loredana Salerno; Anna Maria Panico; Lucia Crascì; Giovanni Puglisi; Giuseppe Romeo
Journal:  Molecules       Date:  2017-05-27       Impact factor: 4.411

3.  Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use.

Authors:  Lisa L Wilson; Shainnel O Eans; Insitar Ramadan-Siraj; Maria N Modica; Giuseppe Romeo; Sebastiano Intagliata; Jay P McLaughlin
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.